Last reviewed · How we verify
Intravenous Famotidine
Intravenous Famotidine is a Small molecule drug developed by Stony Brook University. It is currently FDA-approved. Also known as: H2 Receptor Antagonist.
At a glance
| Generic name | Intravenous Famotidine |
|---|---|
| Also known as | H2 Receptor Antagonist |
| Sponsor | Stony Brook University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases (PHASE1)
- T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers (PHASE1)
- Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity (PHASE3)
- Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia (PHASE1)
- Famotidine and Antacids for Treatment of Dyspepsia (PHASE4)
- Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III) (PHASE1, PHASE2)
- Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Famotidine CI brief — competitive landscape report
- Intravenous Famotidine updates RSS · CI watch RSS
- Stony Brook University portfolio CI
Frequently asked questions about Intravenous Famotidine
What is Intravenous Famotidine?
Intravenous Famotidine is a Small molecule drug developed by Stony Brook University.
Who makes Intravenous Famotidine?
Intravenous Famotidine is developed and marketed by Stony Brook University (see full Stony Brook University pipeline at /company/stony-brook-university).
Is Intravenous Famotidine also known as anything else?
Intravenous Famotidine is also known as H2 Receptor Antagonist.
What development phase is Intravenous Famotidine in?
Intravenous Famotidine is FDA-approved (marketed).
Related
- Manufacturer: Stony Brook University — full pipeline
- Also known as: H2 Receptor Antagonist
- Compare: Intravenous Famotidine vs similar drugs
- Pricing: Intravenous Famotidine cost, discount & access